February 4, 2021

MPN Conference

Update on the Diagnosis and Management of

Myeloproliferative Neoplasms

——————————————————————————————————–

May 1st, 2021

7:30 am – 10:25 am PST

Held Virtually on Zoom


OVERVIEW

The clinical management of BCR-ABL1 negative myeloproliferative neoplasms (MPN) is advancing at a rapid pace. This activity covers the diagnosis, assessment of symptoms burden, and treatment of classical MPN such as polycythemia vera, essential thrombocytosis, and myelofibrosis. The discovery of driver mutations (eg. JAK2V617F) and delineation of the genetic basis of MPNs resulted in significant improvements in the management. ‘Update on the diagnosis of and management of myeloproliferative neoplasms’ is a CME-accredited virtual conference that brings together the leading experts in the United States to discuss recent advances in the management of MPN. This meeting will provide an opportunity to hear from the leading experts on recent advances in MPN, some of which will have immediate clinical applications. Furthermore, each session will also discuss novel emerging treatment options for MPN that may be available in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Advances in the diagnosis and assessment of symptom burden in MPN 
  • Interferon and other novel treatment options for polycythemia and essential thrombocytosis
  • Current approved JAK inhibitors for myelofibrosis and novel emerging treatment options

TARGET AUDIENCE

  • Oncologists
  • Residents/Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses

EDUCATIONAL OBJECTIVES

Upon successful completion of this educational activity, participants will be able to:

  • Review the updated diagnostic criteria and assessment of symptom burden in MPN and integrate into the clinical practice
  • Identify the role of Interferon and other emerging novel treatment options for polycythemia and essential thrombocytosis
  • Describe the currently approved agents and emerging novel targeted therapies for myelofibrosis

CME Credit Statement

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Washington State Medical Association. The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2 hours of Category I CME credit to satisfy the re-licensure requirements of the Washington State Medical Quality Assurance Commission.

The Binaytara Foundation designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2.5 hours of Category I CME credit to satisfy the re-licensure requirements of the Washington State Medical Quality Assurance Commission.

FACULTY

Dr. Srinivas Tantravahi

University of Utah

Independence & Integrity of this educational Activity

Disclosure of off-label product

This educational activity may or may not contain discussions of investigational, unapproved, or off-label products. Participants should consult prescribing information for products discussed during these meetings. Faculties will disclose at the time of presentation if any off-label product being discussed.


Disclosure of Conflict of Interest

The Binaytara Foundation collects disclosure information from all faculty and organizing committee members involved in planning, implementation, and evaluation of our continuing medical education activities. All conflict will be identified and mitigated for everyone in control of the contents of this activity before their participation in this educational activity.

No member of the activity planning committee has any relevant financial relationship with an ACCME defined ineligible entity. 

Faculty disclosure of relevant financial relationship will be provided to participants during the meeting. Participants can also request a copy of the faculty disclosure ahead of time before their participation in this Continuing Medical Education activity. Please contact [email protected] to request the disclosures.